CONSORCIO CENTRO DE INVESTIGACION BIOMEDICA EN RED M.P.

Their core work

CIBER is Spain's national consortium of biomedical research networks, operating under the Carlos III Health Institute (ISCIII). They coordinate thematic research areas — diabetes, rare diseases, cardiovascular disease, mental health, and more — bringing together clinical groups from hospitals and universities across Spain into structured collaborative programs. In H2020, they contribute deep clinical cohort data, patient registries, and multi-omics expertise to large European consortia studying chronic diseases, diagnostics, and translational medicine. They also coordinate targeted projects on rare diseases (Fabry disease) and diabetes interventions in vulnerable populations.

What they specialise in

How they've shifted over time

In the early H2020 period (2015–2018), CIBER focused on foundational biomedical research — graphene-based materials, type 2 diabetes genomics (T2DSystems), and digital monitoring tools (RADAR-CNS). From 2019 onward, the focus shifted markedly toward clinical intervention, translational medicine, and disease stratification: DIABFRAIL-LATAM scaled up a diabetes intervention in Latin America, EJP RD addressed rare disease data sharing, and 3TR tackled treatment non-response through omics-based patient stratification. The trend shows a clear move from basic research participation toward applied, patient-facing clinical programs with international scope.

CIBER is moving from laboratory-scale biomedical research toward real-world clinical intervention trials and omics-driven patient stratification, with increasing activity in cardio-oncology and global health partnerships.

How they like to work

CIBER operates overwhelmingly as a consortium partner (22 of 26 projects), contributing specialized clinical data and patient cohorts to large multi-country consortia — their 731 unique partners across 49 countries reflect a hub-like position in European health research networks. They coordinate selectively: only 2 projects as lead, both in their strongest domain (diabetes and rare metabolic diseases), suggesting they step up to lead when the topic aligns precisely with their clinical networks. Their typical contribution is domain expertise and patient access rather than project management.

With 731 unique consortium partners across 49 countries, CIBER is one of the most broadly connected biomedical research organizations in H2020. Their network spans virtually all of Europe plus Latin America (via DIABFRAIL-LATAM), with particularly dense connections in health, rare diseases, and psychiatric research consortia.

What sets them apart

CIBER is not a single research lab — it is a national meta-network of biomedical research groups spanning all major Spanish hospitals and universities, which means partnering with them gives access to Spain's entire clinical research infrastructure in one agreement. Their dual strength in chronic disease clinical data (diabetes, psychiatry, cardiovascular) and advanced materials for biomedical applications (Graphene Flagship) is an unusual combination rarely found in one organization. For consortium builders, CIBER offers a single entry point to recruit Spanish clinical sites, patient cohorts, and multi-omics capabilities across multiple disease areas.

Highlights from their portfolio

• DIABFRAIL-LATAM
  Largest project by funding (EUR 1.85M) and one of only two they coordinated — scaling a diabetes intervention to Latin America, showing their capacity to lead international clinical programs.
• Smart-4-Fabry
  Their other coordinated project (EUR 1.82M), developing GLA nanoformulations for Fabry disease with GMP manufacturing — demonstrates rare disease therapeutic development capability.
• GrapheneCore1/2/3
  Continuous participation across all three phases of the EU Graphene Flagship (2016–2023), contributing the biomedical application perspective to Europe's largest materials research initiative.